"Fraud on FDA"
Supreme Court finds state law claims based on "fraud on FDA" in device premarket submissions could have adverse consequences on the regulatory balance. The Feb. 21 decision in favor of Buckman Company reverses a lower court ruling in Buckman v. Plaintiffs Legal Committee. The Pharmaceutical Research & Manufacturers of America filed an amicus brief in support of Buckman arguing that the lower court's decision, unless reversed, would improperly permit states to second-guess FDA approval decisions (1"The Pink Sheet" Dec. 11, 2000, p. 15)
You may also be interested in...
FDA's premarket clearance authority could be undermined if states are given power to remedy "fraud on FDA" claims, Supreme Court Justice Antonin Scalia suggested during Dec. 4 arguments for Buckman v. Plaintiffs' Legal Committee.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials